Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Incyte

3 Stocks the World's Greatest Investors Are Buying up Right Now

Skyrocketing inflation, the Fed’s aggressive interest rate hikes, and growing recession fears have kept the stock market under tremendous pressure lately. Amid the market’s downtrend, the world’s renowned investors are scooping up quality stocks Occidental Petroleum (OXY), Amazon.com (AMZN), and Incyte (INCY). Continue reading….

StockNews.com

Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?

Image sourced from Shutterstock

Benzinga

Twitter And 3 Other Stocks Insiders Are Selling

US crude oil futures traded sharply lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Benzinga

Global Cord Blood Stock Gains As FDA Announced Clearance To Study Blood Cancer Candidate

The U.S.

Benzinga

The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy

Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted

The US Patent Trial and Appeal Board (PTAB) issued a final written decision in favor of Concert Pharmaceuticals Inc (NASDAQ:CNCE) regarding the post-grant review (PGR) for the '659 method-of-use patent. The '659 patent claims methods of treating hair loss, including alopecia areata with certain doses of CTP-543, a deuterated form of ruxolitinib, JAK 1/2…

Benzinga

FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19

The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients.

Benzinga

4 Analysts Have This to Say About Incyte

Analysts have provided the following ratings for Incyte (NASDAQ:INCY) within the last quarter:

Benzinga

Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance

Incyte Corporation's (NASDAQ:INCY) Q1 adjusted EPS reached $0.55, compared to $0.67 posted a year ago. Analysts had estimated $0.68. Sales increased 21% Y/Y to $733.24 million, missing the consensus of $750.66 million. The company's operating expenses increased 22% to $616.69 million, with the cost of sales up 45.8%, R&D costs up 15%,…

Benzinga

Incyte: Q1 Earnings Insights

Incyte (NASDAQ:INCY) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

How To Attend Incyte Q1 2022 Earnings Conference Call

Incyte (NASDAQ:INCY) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Incyte (INCY) Conference Call Follow this link to access the live webcast.

Benzinga

Why BriaCell Therapeutics Stock Is Surging Today

BriaCell Therapeutics Corp (NASDAQ: BCTX) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track status to Bria-IMT for the treatment of metastatic breast cancer.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

This Favorable Sign Appears On Incyte's Chart

If history is any guide, there may be good fortune ahead for shares of Incyte (NASDAQ:INCY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Benzinga

The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland

The

Benzinga

FDA Extends Decision Date For Incyte's Ruxolitinib In Vitiligo Skin Disorder

The FDA has extended the review period for Incyte Corporation's (NASDAQ:INCY) supplemental application for ruxolitinib cream (Opzelura) for vitiligo. The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to July 18 from April 18. The FDA extended the PDUFA action date to review additional data from the ongoing Phase 3…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Are Company Insiders Buying These 7 S&P 500 Stocks?

Most investors are likely familiar with the adage, "actions speak louder than words." That saying certainly applies to the executives and other corporate insiders buying and selling shares of their own company's stock.

Benzinga

Insiders Buying Incyte And 2 More Stocks

Although U.S. stock futures traded higher this morning after recording losses on Tuesday, there were a few notable insider trades.

Benzinga

Expert Ratings For Incyte

Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter:

Benzinga

Incyte's Return On Capital Employed Insights

According to Benzinga Pro, during Q4, Incyte (NASDAQ:INCY) earned $563.85 million, a 210.25% increase from the preceding quarter. Incyte also posted a total of $862.85 million in sales, a 6.13% increase since Q3.

Benzinga

Why Are Incyte Shares Trading Lower Today?

Incyte Corporation's (NASDAQ: INCY)

Benzinga

Recap: Incyte Q4 Earnings

Incyte (NASDAQ:INCY) reported its Q4 earnings results on Tuesday, February 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus

Incyte Corporation (NASDAQ: INCY) is

1 2 3

People

Mangeet Kaur BounsMangeet

595 stories

David Tepper

396 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.